Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Purchased by OneDigital Investment Advisors LLC

OneDigital Investment Advisors LLC raised its position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 62.7% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 2,817 shares of the pharmaceutical company’s stock after purchasing an additional 1,086 shares during the quarter. OneDigital Investment Advisors LLC’s holdings in Vertex Pharmaceuticals were worth $1,310,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently made changes to their positions in VRTX. Northwest Investment Counselors LLC bought a new stake in Vertex Pharmaceuticals during the 3rd quarter valued at $25,000. Highline Wealth Partners LLC bought a new stake in shares of Vertex Pharmaceuticals during the third quarter valued at about $27,000. GHP Investment Advisors Inc. acquired a new stake in Vertex Pharmaceuticals in the second quarter worth about $29,000. Stephens Consulting LLC bought a new position in Vertex Pharmaceuticals in the 2nd quarter valued at about $31,000. Finally, Founders Capital Management increased its stake in Vertex Pharmaceuticals by 50.0% during the 2nd quarter. Founders Capital Management now owns 75 shares of the pharmaceutical company’s stock valued at $35,000 after buying an additional 25 shares during the period. Institutional investors own 90.96% of the company’s stock.

Insider Activity at Vertex Pharmaceuticals

In related news, Director Sangeeta N. Bhatia sold 646 shares of the stock in a transaction dated Friday, August 30th. The shares were sold at an average price of $500.00, for a total value of $323,000.00. Following the completion of the transaction, the director now owns 4,435 shares of the company’s stock, valued at $2,217,500. This represents a 12.71 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Chairman Jeffrey M. Leiden sold 3,784 shares of Vertex Pharmaceuticals stock in a transaction that occurred on Friday, August 30th. The shares were sold at an average price of $499.00, for a total value of $1,888,216.00. Following the sale, the chairman now directly owns 9,994 shares in the company, valued at $4,987,006. The trade was a 27.46 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.20% of the stock is currently owned by company insiders.

Vertex Pharmaceuticals Price Performance

NASDAQ VRTX opened at $467.01 on Tuesday. The company has a quick ratio of 2.20, a current ratio of 2.47 and a debt-to-equity ratio of 0.01. The stock has a market capitalization of $120.27 billion, a PE ratio of -234.68 and a beta of 0.39. Vertex Pharmaceuticals Incorporated has a 12-month low of $346.29 and a 12-month high of $519.88. The company has a 50 day moving average price of $476.31 and a two-hundred day moving average price of $472.56.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its earnings results on Monday, November 4th. The pharmaceutical company reported $4.38 EPS for the quarter, topping the consensus estimate of $3.61 by $0.77. Vertex Pharmaceuticals had a negative net margin of 4.52% and a negative return on equity of 1.91%. The firm had revenue of $2.77 billion for the quarter, compared to the consensus estimate of $2.69 billion. During the same period in the prior year, the business posted $3.67 earnings per share. The business’s quarterly revenue was up 11.6% on a year-over-year basis. As a group, equities analysts predict that Vertex Pharmaceuticals Incorporated will post -1.82 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

VRTX has been the subject of a number of research analyst reports. Scotiabank upped their price target on shares of Vertex Pharmaceuticals from $480.00 to $486.00 and gave the stock a “sector perform” rating in a research note on Tuesday, November 5th. Barclays downgraded Vertex Pharmaceuticals from an “overweight” rating to an “equal weight” rating and upped their target price for the stock from $472.00 to $509.00 in a research report on Monday, August 5th. Piper Sandler lifted their price target on Vertex Pharmaceuticals from $500.00 to $535.00 and gave the company an “overweight” rating in a research report on Friday, August 2nd. Canaccord Genuity Group raised their target price on Vertex Pharmaceuticals from $361.00 to $408.00 and gave the company a “sell” rating in a research note on Wednesday, November 6th. Finally, Raymond James reiterated a “market perform” rating on shares of Vertex Pharmaceuticals in a research report on Thursday, October 10th. Three investment analysts have rated the stock with a sell rating, nine have issued a hold rating, seventeen have given a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $499.12.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.